179 related articles for article (PubMed ID: 10964567)
1. Structural basis for isotype selectivity of the human retinoic acid nuclear receptor.
Klaholz BP; Mitschler A; Moras D
J Mol Biol; 2000 Sep; 302(1):155-70. PubMed ID: 10964567
[TBL] [Abstract][Full Text] [Related]
2. RARbeta ligand-binding domain bound to an SRC-1 co-activator peptide: purification, crystallization and preliminary X-ray diffraction analysis.
Kammerer S; Germain P; Flaig R; Peluso-Iltis C; Mitschler A; Rochel N; Gronemeyer H; Moras D
Acta Crystallogr D Biol Crystallogr; 2004 Nov; 60(Pt 11):2048-50. PubMed ID: 15502323
[TBL] [Abstract][Full Text] [Related]
3. Structural basis for engineering of retinoic acid receptor isotype-selective agonists and antagonists.
Géhin M; Vivat V; Wurtz JM; Losson R; Chambon P; Moras D; Gronemeyer H
Chem Biol; 1999 Aug; 6(8):519-29. PubMed ID: 10421757
[TBL] [Abstract][Full Text] [Related]
4. Retinoic acid receptor beta,gamma-selective ligands: synthesis and biological activity of 6-substituted 2-naphthoic acid retinoids.
Yu KL; Spinazze P; Ostrowski J; Currier SJ; Pack EJ; Hammer L; Roalsvig T; Honeyman JA; Tortolani DR; Reczek PR; Mansuri MM; Starrett JE
J Med Chem; 1996 Jun; 39(12):2411-21. PubMed ID: 8691435
[TBL] [Abstract][Full Text] [Related]
5. Synthetic retinoids: structure-activity relationships.
Barnard JH; Collings JC; Whiting A; Przyborski SA; Marder TB
Chemistry; 2009 Nov; 15(43):11430-42. PubMed ID: 19821467
[TBL] [Abstract][Full Text] [Related]
6. Effects of ligand binding on the association properties and conformation in solution of retinoic acid receptors RXR and RAR.
Egea PF; Rochel N; Birck C; Vachette P; Timmins PA; Moras D
J Mol Biol; 2001 Mar; 307(2):557-76. PubMed ID: 11254382
[TBL] [Abstract][Full Text] [Related]
7. Density functional and docking studies of retinoids for cancer treatment.
Silva CH; Almeida P; Taft CA
J Mol Model; 2004 Feb; 10(1):38-43. PubMed ID: 14634847
[TBL] [Abstract][Full Text] [Related]
8. C3 halogen and c8'' substituents on stilbene arotinoids modulate retinoic Acid receptor subtype function.
Alvarez S; Khanwalkar H; Alvarez R; Erb C; Martínez C; Rodríguez-Barrios F; Germain P; Gronemeyer H; de Lera AR
ChemMedChem; 2009 Oct; 4(10):1630-40. PubMed ID: 19670208
[TBL] [Abstract][Full Text] [Related]
9. Identification of retinoids with nuclear receptor subtype-selective activities.
Lehmann JM; Dawson MI; Hobbs PD; Husmann M; Pfahl M
Cancer Res; 1991 Sep; 51(18):4804-9. PubMed ID: 1654201
[TBL] [Abstract][Full Text] [Related]
10. Structure, function and modulation of retinoic acid receptor beta, a tumor suppressor.
Alvarez S; Germain P; Alvarez R; Rodríguez-Barrios F; Gronemeyer H; de Lera AR
Int J Biochem Cell Biol; 2007; 39(7-8):1406-15. PubMed ID: 17433757
[TBL] [Abstract][Full Text] [Related]
11. Arginine of retinoic acid receptor beta which coordinates with the carboxyl group of retinoic acid functions independent of the amino acid residues responsible for retinoic acid receptor subtype ligand specificity.
Zhang ZP; Hutcheson JM; Poynton HC; Gabriel JL; Soprano KJ; Soprano DR
Arch Biochem Biophys; 2003 Jan; 409(2):375-84. PubMed ID: 12504905
[TBL] [Abstract][Full Text] [Related]
12. Pyrazine arotinoids with inverse agonist activities on the retinoid and rexinoid receptors.
García J; Khanwalkar H; Pereira R; Erb C; Voegel JJ; Collette P; Mauvais P; Bourguet W; Gronemeyer H; de Lera AR
Chembiochem; 2009 May; 10(7):1252-9. PubMed ID: 19343742
[TBL] [Abstract][Full Text] [Related]
13. Retinoid receptor subtype-selective modulators through synthetic modifications of RARgamma agonists.
Alvarez S; Alvarez R; Khanwalkar H; Germain P; Lemaire G; Rodríguez-Barrios F; Gronemeyer H; de Lera AR
Bioorg Med Chem; 2009 Jul; 17(13):4345-59. PubMed ID: 19482478
[TBL] [Abstract][Full Text] [Related]
14. Ligand recognition by RAR and RXR receptors: binding and selectivity.
Sussman F; de Lera AR
J Med Chem; 2005 Oct; 48(20):6212-9. PubMed ID: 16190748
[TBL] [Abstract][Full Text] [Related]
15. Molecular basis for designing selective modulators of retinoic acid receptor transcriptional activities.
Lefebvre P
Curr Drug Targets Immune Endocr Metabol Disord; 2001 Aug; 1(2):153-64. PubMed ID: 12476796
[TBL] [Abstract][Full Text] [Related]
16. Marked improvement induced in photoaged skin of hairless mouse by ER36009, a novel RARgamma-specific retinoid, but not by ER35794, an RXR-selective agonist.
Sakuta T; Kanayama T
Int J Dermatol; 2006 Nov; 45(11):1288-95. PubMed ID: 17076708
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the differential coregulator binding signatures of the Retinoic Acid Receptor subtypes upon (ant)agonist action.
Miro Estruch I; Melchers D; Houtman R; de Haan LHJ; Groten JP; Louisse J; Rietjens IMCM
Biochim Biophys Acta Proteins Proteom; 2017 Sep; 1865(9):1195-1206. PubMed ID: 28642153
[TBL] [Abstract][Full Text] [Related]
18. Design of selective nuclear receptor modulators: RAR and RXR as a case study.
de Lera AR; Bourguet W; Altucci L; Gronemeyer H
Nat Rev Drug Discov; 2007 Oct; 6(10):811-20. PubMed ID: 17906643
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and characterization of heteroarotinoids demonstrate structure specificity relationships.
Benbrook DM; Subramanian S; Gale JB; Liu S; Brown CW; Boehm MF; Berlin KD
J Med Chem; 1998 Sep; 41(19):3753-7. PubMed ID: 9733501
[TBL] [Abstract][Full Text] [Related]
20. Three-dimensional models of estrogen receptor ligand binding domain complexes, based on related crystal structures and mutational and structure-activity relationship data.
Wurtz JM; Egner U; Heinrich N; Moras D; Mueller-Fahrnow A
J Med Chem; 1998 May; 41(11):1803-14. PubMed ID: 9599231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
